Summary of TLR2/4 and RAGE pathway enrichment
| Treatment group | TLR2/4 pathway | RAGE pathway |
|---|---|---|
| Untreated control | Enriched (FDR = 0.108) | Not enriched |
| RT + GVAX + αPD-1 + CCR2/5i | Not enriched | Not enriched |
| RT + αPD-1 + CCR2/5i | Not enriched | Not enriched |
| RT + CCR2/5i | Not enriched | Not enriched |
| RT + αPD-1 | Enriched (FDR = 0.059) | Enriched (FDR = 0.205) |
| RT only | Enriched (FDR = 0.075) | Enriched (FDR = 0.065) |
| GVAX + αPD-1 + CCR2/5i | Enriched (FDR = 0.081) | Not enriched |
| Treatment group | TLR2/4 pathway | RAGE pathway |
|---|---|---|
| Untreated control | Enriched (FDR = 0.108) | Not enriched |
| RT + GVAX + αPD-1 + CCR2/5i | Not enriched | Not enriched |
| RT + αPD-1 + CCR2/5i | Not enriched | Not enriched |
| RT + CCR2/5i | Not enriched | Not enriched |
| RT + αPD-1 | Enriched (FDR = 0.059) | Enriched (FDR = 0.205) |
| RT only | Enriched (FDR = 0.075) | Enriched (FDR = 0.065) |
| GVAX + αPD-1 + CCR2/5i | Enriched (FDR = 0.081) | Not enriched |
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.